IBDEI09T ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4551,1,3,0)
 ;;=3^ALTEPLASE RECOMBINANT PER 1 MG
 ;;^UTILITY(U,$J,358.3,4552,0)
 ;;=J3260^^38^441^39^^^^1
 ;;^UTILITY(U,$J,358.3,4552,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4552,1,2,0)
 ;;=2^J3260
 ;;^UTILITY(U,$J,358.3,4552,1,3,0)
 ;;=3^TOBRAMYCIN SULFATE PER 80 MG
 ;;^UTILITY(U,$J,358.3,4553,0)
 ;;=J7682^^38^441^38^^^^1
 ;;^UTILITY(U,$J,358.3,4553,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4553,1,2,0)
 ;;=2^J7682
 ;;^UTILITY(U,$J,358.3,4553,1,3,0)
 ;;=3^TOBRAMYCIN NON-COM UNIT 300 MG
 ;;^UTILITY(U,$J,358.3,4554,0)
 ;;=P9047^^38^441^2^^^^1
 ;;^UTILITY(U,$J,358.3,4554,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4554,1,2,0)
 ;;=2^P9047
 ;;^UTILITY(U,$J,358.3,4554,1,3,0)
 ;;=3^ALBUMIN (HUMAN), 25%, 50ML
 ;;^UTILITY(U,$J,358.3,4555,0)
 ;;=J0886^^38^441^16^^^^1
 ;;^UTILITY(U,$J,358.3,4555,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4555,1,2,0)
 ;;=2^J0886
 ;;^UTILITY(U,$J,358.3,4555,1,3,0)
 ;;=3^EPOETIN ALFA 1000 UNITS ESRD
 ;;^UTILITY(U,$J,358.3,4556,0)
 ;;=J3370^^38^441^41^^^^1
 ;;^UTILITY(U,$J,358.3,4556,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4556,1,2,0)
 ;;=2^J3370
 ;;^UTILITY(U,$J,358.3,4556,1,3,0)
 ;;=3^VANCOMYCIN HCL 500 MG
 ;;^UTILITY(U,$J,358.3,4557,0)
 ;;=J0636^^38^441^4^^^^1
 ;;^UTILITY(U,$J,358.3,4557,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4557,1,2,0)
 ;;=2^J0636
 ;;^UTILITY(U,$J,358.3,4557,1,3,0)
 ;;=3^CALCITRIOL INJ PER 0.1 MCG
 ;;^UTILITY(U,$J,358.3,4558,0)
 ;;=J0882^^38^441^9^^^^1
 ;;^UTILITY(U,$J,358.3,4558,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4558,1,2,0)
 ;;=2^J0882
 ;;^UTILITY(U,$J,358.3,4558,1,3,0)
 ;;=3^DARBEPOETIN ALFA,ESRD USE 1MCG
 ;;^UTILITY(U,$J,358.3,4559,0)
 ;;=J3490^^38^441^27^^^^1
 ;;^UTILITY(U,$J,358.3,4559,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4559,1,2,0)
 ;;=2^J3490
 ;;^UTILITY(U,$J,358.3,4559,1,3,0)
 ;;=3^LITHIUM CARBONATE
 ;;^UTILITY(U,$J,358.3,4560,0)
 ;;=J3490^^38^441^29^^^^1
 ;;^UTILITY(U,$J,358.3,4560,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4560,1,2,0)
 ;;=2^J3490
 ;;^UTILITY(U,$J,358.3,4560,1,3,0)
 ;;=3^MIDODRINE
 ;;^UTILITY(U,$J,358.3,4561,0)
 ;;=J0881^^38^441^10^^^^1
 ;;^UTILITY(U,$J,358.3,4561,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4561,1,2,0)
 ;;=2^J0881
 ;;^UTILITY(U,$J,358.3,4561,1,3,0)
 ;;=3^DARBEPOETIN ALFA,NON-ESRD USE 1 MCG
 ;;^UTILITY(U,$J,358.3,4562,0)
 ;;=J0885^^38^441^17^^^^1
 ;;^UTILITY(U,$J,358.3,4562,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4562,1,2,0)
 ;;=2^J0885
 ;;^UTILITY(U,$J,358.3,4562,1,3,0)
 ;;=3^EPOETIN ALFA 1000 UNITS NON-ESRD
 ;;^UTILITY(U,$J,358.3,4563,0)
 ;;=J7060^^38^441^1^^^^1
 ;;^UTILITY(U,$J,358.3,4563,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4563,1,2,0)
 ;;=2^J7060
 ;;^UTILITY(U,$J,358.3,4563,1,3,0)
 ;;=3^5% DEXTROSE/WATER 500 ML=1 UNIT
 ;;^UTILITY(U,$J,358.3,4564,0)
 ;;=J0895^^38^441^11^^^^1
 ;;^UTILITY(U,$J,358.3,4564,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4564,1,2,0)
 ;;=2^J0895
 ;;^UTILITY(U,$J,358.3,4564,1,3,0)
 ;;=3^DEFEROXAMINE MESYLATE 500 MG
 ;;^UTILITY(U,$J,358.3,4565,0)
 ;;=J1160^^38^441^12^^^^1
 ;;^UTILITY(U,$J,358.3,4565,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4565,1,2,0)
 ;;=2^J1160
 ;;^UTILITY(U,$J,358.3,4565,1,3,0)
 ;;=3^DIGOXIN UP TO 5 MG
 ;;^UTILITY(U,$J,358.3,4566,0)
 ;;=J1815^^38^441^23^^^^1
 ;;^UTILITY(U,$J,358.3,4566,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4566,1,2,0)
 ;;=2^J1815
 ;;^UTILITY(U,$J,358.3,4566,1,3,0)
 ;;=3^INSULIN PER 5 UNITS
 ;;^UTILITY(U,$J,358.3,4567,0)
 ;;=J2320^^38^441^30^^^^1
 ;;^UTILITY(U,$J,358.3,4567,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4567,1,2,0)
 ;;=2^J2320
 ;;^UTILITY(U,$J,358.3,4567,1,3,0)
 ;;=3^NANDROLONE DECANOATE UP TO 50 MG
